CME Group posted second quarter earnings of $1.97 per share, exceeding the Zacks Consensus Estimate of $1.92 per share. The figure is higher than the year-ago quarter’s $1.64 per share.
The company’s revenues came in at $1.24 billion for the quarter, missing the Zacks Consensus Estimate by 0.77%. Revenues were $1.18 billion a year ago.
Following their earnings release, research analysts at Oppenheimer lowered their Q3 2022 earnings estimates for CME Group to $1.92 for the quarter, vs. their previous forecast of $1.95. Oppenheimer has a “Outperform” rating and a $223.00 price target on the shares.
CME saw its Momentum Indicator move below the 0 level on May 18, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 102 similar instances where the indicator turned negative. In of the 102 cases, the stock moved further down in the following days. The odds of a decline are at .
CME moved below its 50-day moving average on May 02, 2023 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CME crossed bearishly below the 50-day moving average on May 04, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CME entered a downward trend on May 25, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator entered the oversold zone -- be on the watch for CME's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in of 354 cases, the price rose further within the following month. The odds of a continued upward trend are .
CME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CME’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.325) is normal, around the industry mean (3.571). P/E Ratio (22.472) is within average values for comparable stocks, (35.975). CME's Projected Growth (PEG Ratio) (3.766) is slightly higher than the industry average of (2.230). Dividend Yield (0.043) settles around the average of (0.038) among similar stocks. P/S Ratio (12.438) is also within normal values, averaging (105.886).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows